We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-5.2%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.55B
AUM Growth
-$395M
Cap. Flow
+$563M
Cap. Flow %
15.85%
Top 10 Hldgs %
43.38%
Holding
114
New
26
Increased
23
Reduced
23
Closed
40

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$187M
2
PFE icon
Pfizer
PFE
+$168M
3
GILD icon
Gilead Sciences
GILD
+$125M
4
UNH icon
UnitedHealth
UNH
+$125M
5
LLY icon
Eli Lilly
LLY
+$93.4M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$84.3M
2
AAPL icon
Apple
AAPL
+$80.7M
3
BRCM
BROADCOM CORP CL-A
BRCM
+$75.5M
4
LBTYK icon
Liberty Global Class C
LBTYK
+$74M
5
VMW
VMware, Inc
VMW
+$72.2M

Sector Composition

Rank Sector Weight
1 Healthcare 59.47%
2 Communication Services 6.34%
3 Financials 5.66%
4 Technology 4.95%
5 Consumer Discretionary 4.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLTQ
51
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$14.3M 0.4%
+445,686
New +$14.8M
BCR
52
DELISTED
CR Bard Inc.
BCR
$14.1M 0.4%
+75,570
New +$14.3M
TXT icon
53
Textron
TXT
$14.7B
$13.5M 0.38%
+357,388
New +$14.8M
HDP
54
DELISTED
Hortonworks, Inc.
HDP
$12.9M 0.36%
589,489
-299,690
-34% -$7.44M
ADAP
55
DELISTED
Adaptimmune Therapeutics
ADAP
$12M 0.34%
1,002,953
+37,438
+4% +$529K
DBVT
56
DBV Technologies
DBVT
$813M
$9.75M 0.27%
+27,397
New +$10.8M
CHRS icon
57
Coherus Oncology
CHRS
$217M
$5.92M 0.17%
295,579
+7,500
+3% +$228K
FOMX
58
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.72M 0.1%
506,920
+60,011
+13% +$612K
JUNO
59
DELISTED
Juno Therapeutics, Inc.
JUNO
$3M 0.08%
73,631
-45,323
-38% -$1.99M
AGN
60
CALL
DELISTED
Allergan plc
AGN
$2.52M 0.07%
+314,700
New +$96.7M
RGNX icon
61
Regenxbio
RGNX
$616M
$2.36M 0.07%
+107,305
New +$2.74M
MRK icon
62
PUT
Merck
MRK
$322B
$1.75M 0.05%
+1,363,762
New +$72.4M
KYTH
63
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$1.54M 0.04%
20,589
-472,257
-96% -$35.3M
PTCT icon
64
CALL
PTC Therapeutics
PTCT
$6.18B
$1.31M 0.04%
+428,200
New +$18.3M
MXL icon
65
MaxLinear
MXL
$5.19B
$1.01M 0.03%
81,398
-111,336
-58% -$1.23M
TEVA icon
66
CALL
Teva Pharmaceuticals
TEVA
$40.4B
$1.01M 0.03%
+2,713,000
New +$176M
BMY icon
67
CALL
Bristol-Myers Squibb
BMY
$129B
$419K 0.01%
+2,537,100
New +$161M
KERX
68
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$344K 0.01%
+97,687
New +$654K
TDOC icon
69
Teladoc Health
TDOC
$1.66B
$305K 0.01%
+13,670
New +$369K
PFE icon
70
CALL
Pfizer
PFE
$143B
$265K 0.01%
+2,326,600
New +$74.6M
ROK icon
71
CALL
Rockwell Automation
ROK
$51.1B
$87K ﹤0.01%
+388,600
New +$44M
MCK icon
72
CALL
McKesson
MCK
$104B
$26K ﹤0.01%
+343,100
New +$72.7M
AAPL icon
73
CALL
Apple
AAPL
$4.97T
– –
-2,264,400
Closed -$303K
AAPL icon
74
Apple
AAPL
$4.97T
– –
-2,573,348
Closed -$80.7M
ACHC icon
75
Acadia Healthcare
ACHC
$2.55B
– –
-227,174
Closed -$17.8M
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
AC
AWM Capital Phoenix, Arizona $1.1B AUM 15.03% 1-Year Est. Return

PFM Health Sciences's Q3 2015 Portfolio in Review

As of Q3 2015, PFM Health Sciences held 114 positions worth $3.55B, down 10% from $3.95B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

PFM Health Sciences deployed $563M of net new capital in Q3 2015, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was Allergan plc: 608,789 shares worth $165M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 48% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was BROADCOM CORP CL-A, an estimated $75.5M trimmed.

  • PFM Health Sciences's largest Q3 2015 buy was Allergan plc: 608,789 shares worth $165M.
  • PFM Health Sciences added most to Pfizer in Q3 2015, an estimated $168M increase.
  • PFM Health Sciences's biggest Q3 2015 reduction was BROADCOM CORP CL-A, cutting an estimated $75.5M.
  • PFM Health Sciences fully exited Elevance Health in Q3 2015, selling an estimated $84.3M.
  • PFM Health Sciences's ten largest holdings make up 43% of its $3.55B portfolio in Q3 2015.
  • PFM Health Sciences opened 26 new positions and closed 40 in Q3 2015.
  • PFM Health Sciences's portfolio value fell 10% quarter-over-quarter to $3.55B.

Based on PFM Health Sciences's 13F filing for Q3 2015, filed 16 Nov 2015.